OT-551

DB05650InvestigationalSmall molecule

OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the... It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by protecting against retina photoreceptor...

Primary indication: Investigated for use/treatment in cataracts, eye disorders/infections, glaucoma, and macular degeneration.Curator reviewed
Formula / weight: C₁₃H₂₃NO₃ · 241.331 g/mol (avg)
Code names: OT-551

Resolves to

Compound

UNIIDZ02S3A31NCAS627085-11-4PubChem10131000

Structure

InChIKeyZWEXEKJLDHNLLA-UHFFFAOYSA-NSMILESCC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1

Targets

Q16236NFE2L2

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with OT-551, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account